Physician profile
Thomas Davis
NPI 1710982822
$9,048.60
in general payments reported to CMS, 2019-2025
35 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,941 · 2020: $1,502 · 2021: $1,631 · 2022: $1,119 · 2023: $301 · 2024: $254 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $839 · Education: $15.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $839.46 |
| Education | $15.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,545.67 | 2019-2025 | Talvey, Darzalex, Tecvayli |
| Verastem, INC. | $1,320.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $1,234.31 | 2021 | |
| Cti Biopharma Corp. | $1,015.38 | 2022-2023 | Vonjo |
| Pfizer INC. | $436.61 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $202.97 | 2019-2025 | |
| Astellas Pharma US INC | $134.49 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $97.72 | 2019-2021 | |
| Eisai INC. | $84.11 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $79.96 | 2019-2025 | Keytruda |
| Genzyme Corporation | $78.83 | 2020-2023 | |
| Genentech USA, INC. | $77.73 | 2019-2025 | Polivy, Tecentriq |
| Janssen Scientific Affairs, LLC | $72.21 | 2019-2020 | |
| Taiho Oncology, INC. | $71.11 | 2019-2024 | |
| Incyte Corporation | $49.79 | 2021-2024 | Jakafi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $46.88 | 2019-2024 | Alunbrig |
| Daiichi Sankyo INC. | $46.87 | 2019-2020 | |
| Tempus Ai, INC | $46.66 | 2024-2025 | Xt Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.95 | 2019-2020 | |
| Foundation Medicine, INC. | $39.50 | 2021 | |
| Aurobindo Pharma USA, INC. | $38.23 | 2019 | |
| Array Biopharma INC | $35.84 | 2024 | Braftovi, Tukysa, Mektovi |
| Astrazeneca Pharmaceuticals Lp | $31.13 | 2023-2025 | Calquence |
| Emd Serono, INC. | $30.75 | 2023-2025 | Bavencio |
| Mirati Therapeutics, INC. | $28.82 | 2023-2024 | Krazati |
| Tg Therapeutics, INC. | $26.40 | 2021 | |
| Amag Pharmaceuticals, INC. | $25.63 | 2019 | |
| Gilead Sciences, INC. | $24.36 | 2021-2022 | |
| Sobi, INC | $16.74 | 2025 | |
| Alexion Pharmaceuticals, INC. | $16.59 | 2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $13.94 | 2023 | |
| Global Blood Therapeutics, INC. | $12.69 | 2021 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 | |
| Tesaro, INC. | $11.28 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.